These observations are consistent with the premise that high IGFBP-3 expression in TNBC cell lines is a major driver of cell proliferation through the EGFR and S1P pathways [13], and suggests that since high tumor IGFBP-3 expression is required for the drugs to act synergistically, tissue IGFBP-3 might be evaluated as a biomarker for the efficacy of EGFR-TKI-FTY720 combination therapy. The gene discussed is MBTPS1; the disease is neoplasm.